We would love to hear your thoughts about our site and services, please take our survey here.
2-3 million to cover salaries, promotions, advertisements, workings for next 3-6 months. Then cash rich from income generated with business.
Covid ain’t going anywhere,it’s here for 12 months.
Gaming is evolving fast and new consoles out in a few weeks. We have the ex ceo Sony superstar don’t forget. Look what he did for the PlayStation 4 . Figures prove his worth.
I find it more amazing how fellow de dampers follow Tomtit, who don’t hold any shares in a company but pay more attention and time on it.
Who’s the daftest ?
Easiest way to do this, is read the informative rns just released and take note...... important.
Then read this.... from yesterday
https://www.mediapost.com/publications/article/351842/advertising-enters-video-games-at-a-new-angle-thro.html
Put the links together......... and also the viewing figures for Watched professional games and targeting ads...
Next sp target is 30p. It has been a nice steady rise up to now, looking very promising .
All positive update, customers, partners, revenues. Global reach, growing market, Very strong team of experience.
New consoles released over next couple of months, it’s going to be a massive market.
Sense of panic coming across intrepid lol, not heard owt for days then wham.... all over the board
28 May 2020
e-therapeutics plc
Expansion to encompass RNA interference (RNAi) as a new therapeutic modality and the formation of a Scientific Advisory Board (SAB)
Oxford, UK, 28th May 2020: e-therapeutics plc (AIM: ETX.L, "e-therapeutics" or "the Company") today announces its expansion into RNA interference (RNAi) as a therapeutic modality to pursue drug discovery outcomes and the creation of a Scientific Advisory Board headed by Dr Paul Burke.
e-therapeutics has a unique computational approach to drug discovery. Its Network-driven Drug Discovery (NDD) platform leverages its machine learning-enhanced database of over 15 million small molecule compounds to perform functional in silico phenotypic screens. In addition, its Genome-Associated Interactions Network (GAINs) proprietary platform enables the Company to distil actionable outcomes from complex genomic datasets. GAINs outputs are well suited to genetic medicine approaches as therapeutic interventions. As such, RNAi is an area that the Company plans to explore to harness computational drug discovery outcomes, both internally and in partnership with collaborators.
In addition, the Company has appointed Dr Paul Burke, Principal of Burke Bioventures LLC, as Chair of the Scientific Advisory Board (SAB). Dr Burke will work with the Company to appoint additional international advisors of the highest calibre to its newly formed SAB. Experience of SAB members will include genetics, computational approaches to drug discovery and deep drug development expertise, across small molecules and RNAi.
Dr Burke brings over two decades of biopharmaceutical industry experience across a broad range of therapeutic modalities. Paul was the founding head of Pfizer's global Center of Excellence for targeted drug delivery and imaging and Chief Technology Officer of its oligonucleotide therapeutics unit. Prior to that, he was Executive Director, RNA Therapeutics at Merck & Co. Paul previously built a decade-long career at Amgen, most recently serving as Executive Director, Pharmaceutics. Dr Burke received his BSc in Chemistry from Harvey Mudd College and his PhD in Biological Chemistry from MIT, and is currently Affiliate Professor of Bioengineering at the University of Washington.
Dr Paul Burke commented: "I am excited by the potential of e-therapeutics' platform technologies to critically inform the drug discovery process in a way that can generate not only novel small molecule candidates, but also those that are based on RNA, an important, emerging therapeutic modality. I look forward to working with the company to build a high calibre scientific advisory board that can provide meaningful insight and guidance to help them achieve their strategic and commercial goals."
Ali Mortazavi, Executive Chairman, said: "We are delighted to be working closely with Paul as we maximise the applicability of our computational technologies across therapeutic areas to transform the drug disco
Codemasters Group Holdings Plc
("Codemasters" or the "Company")
Fast & Furious Crossroads Launch Update
Further to the Company's announcements on 13 December 2019 and 13 March 2020, the Board of Codemasters is pleased to provide an update regarding the launch of Fast & Furious Crossroads (the "F&F Game"), the licensed IP game that is being developed by recently acquired studio, Slightly Mad Studios, originally scheduled for release in May 2020.
Following close consultation with our partners at BANDAI NAMCO Entertainment Europe and Universal Games and Digital Platforms, the Company can confirm that an agreement has been reached to launch the F&F Game in the second quarter of the Company's current financial year, being the three months to 30 September 2020.
Accordingly, the Board of Codemasters confirms that this later launch date is not expected to have a material impact on its financial expectations for FY21.
Is their something you would like to share ? Insider information ;-) ?
More big trades after hours.
I would like to know how e-therapeutics are going forward as a business, do they charge a fee or is it a % of a proven product to which a drug is made and sold.
They must be inundated with work at the moment and for the for foreseeable future, as countries ease spending on military and invest in bio science, I would of thought. No one will be wanting to get caught with their pants down again.
I only bought in at 12p so don’t have a massive amount. Couple of ££ would be nice, not greedy lol.
What a lemon.
The share price of itm,cwr is more of a positive on afc than anything else atm. Beginning to make it a speculative punt with the low sp, also some profits might come this way.
Have to say that’s well worth a watch, partners already lined up ready and waiting.
Whoever gets the golden ticket, China should be the one who funds it, and pays for the entire population.
Tw wants to read his own small print... what a k*@b..
In particular, the information does not constitute any form of advice or recommendation by SharePrats.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Even if the virus dies down it’s not going away. Countries will want stocks of kits at hand to test quickly when needed. Long way to go with all of this.
Ha Tw, can’t even look at them initials without rolling my eyes like a teenager. Bored already. Jog on
Nice steady rise on a red day, looking good.
Would be more useful atm.
Last week, the U.K. government announced a £2 billion package “to create a new era for cycling and walking.” That includes £250 million to establish new bike lanes and safer junctions in England. Similar initiatives are being announced in other countries: German cities are re-marking roads to create “pop-up” cycles lanes, for example.
At the same time, the government said it plans to fast-track trials of e-scooters, which are technically still illegal in the U.K. Trials are to be brought forward from next year to next month and they’re going to be nationwide instead of in just four parts of the U.K.
So, since the Afc promotional team have had plenty of time working from home, and there has been an opportunity to refresh update and promote all the great work Afc have been up to, what have we had?
I see the website is stagnant from jan feb.
1 LinkedIn post .....
And errrrr.....
Even tho I’m out, I still get disappointed.
A few new pictures of tech, cell, something in the lab. Anything....
It does seem cheap compared to itm,pps,cwr, but their is a reason for that and everyone knows it. Otherwise it would be 20p+
The government are going to be furloughed to November, I can’t see many big spending subsidies or grants after all this.